Entrada Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Entrada Therapeutics Inc.
- Former names
- CycloPorters, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TRDA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001689375
- EIN
- 81-3983399
Board of directors
-
Bernhardt G. Zeiher · DirectorSince 2023
-
Dipal Doshi · Director · CEOSince 2023
-
Gina Chapman · DirectorSince 2023
-
John F. Crowley · DirectorSince 2023
-
Kush Parmar · DirectorSince 2023
-
Maha Radhakrishnan · DirectorSince 2025
- Since 2023
-
Peter S. Kim · DirectorSince 2023
Chief executives
Dipal Doshi
· President and CEO
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.4%
-
92.0%
Board connections
6 of this board's directors also sit on 11 other boards.
- via Bernhardt G. Zeiher
- via Mary Thistle
- via Mary Thistle
- via Maha Radhakrishnan
- via Bernhardt G. Zeiher
- via Dipal Doshi
- via Maha Radhakrishnan
- via Mary Thistle
- via John F. Crowley
- via Mary Thistle
- via Kush Parmar
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,643,402
- 17 purchases by 3 insiders
- Sold, last 12 months
- $15,103,785
- 44 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 9, 2026 | MPM BioVentures 2014, L.P. 10% owner | Open-market sale | −28,837 | $7.13 | $205,608 |
| Sep 9, 2026 | MPM BIOVENTURES 2018, L.P. 10% owner | Open-market sale | −28,837 | $7.13 | $205,608 |
| Sep 8, 2026 | MPM BioVentures 2014, L.P. 10% owner | Open-market sale | −192,500 | $7.41 | $1,426,425 |
| Sep 8, 2026 | MPM BIOVENTURES 2018, L.P. 10% owner | Open-market sale | −192,500 | $7.41 | $1,426,425 |
| Sep 4, 2026 | MPM BioVentures 2014, L.P. 10% owner | Open-market sale | −38,500 | $7.11 | $273,735 |
| Sep 4, 2026 | MPM BIOVENTURES 2018, L.P. 10% owner | Open-market sale | −38,500 | $7.11 | $273,735 |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. 10% owner | Open-market sale | −32,263 | $7.17 | $231,326 |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. 10% owner | Open-market sale | −32,263 | $7.17 | $231,326 |
| Sep 2, 2026 | Dipal Doshi Director, Officer (CEO) | Shares withheld for tax | −8,724 | $7.14 | $62,323 |
| Sep 2, 2026 | Dowden Nathan J Officer (President & COO) | Shares withheld for tax | −2,528 | $7.14 | $18,060 |
| Sep 2, 2026 | WENTWORTH KORY JAMES Officer (Chief Financial Officer) | Shares withheld for tax | −1,733 | $7.14 | $12,380 |
| Sep 2, 2026 | Sethuraman Natarajan Officer (President, Research & Develop.) | Shares withheld for tax | −2,079 | $7.14 | $14,852 |
| Sep 2, 2026 | MPM BioVentures 2014, L.P. 10% owner | Open-market sale | −25,131 | $7.19 | $180,692 |
| Sep 2, 2026 | MPM BIOVENTURES 2018, L.P. 10% owner | Open-market sale | −25,131 | $7.19 | $180,692 |
| Sep 1, 2026 | MPM BioVentures 2014, L.P. 10% owner | Open-market sale | −29,088 | $7.06 | $205,361 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.